Letter: Most Favored Nation Drug Pricing Model Encourages Discriminatory Metrics

In a recent letter to the Office of the United States Trade Representative, the Alliance for Aging Research opposes the proposed “Most Favored Nation” (MFN) drug pricing model, noting that it would reduce access to therapies for older Americans.

The letter warns that tying U.S. drug prices to foreign systems could import discriminatory practices like QALY metrics, which undervalue older adults and individuals with a disability. Instead, the Alliance urges trade policies that promote global investment in R&D and protect patient-centered care.

Read the full letter.